文献速递浆细胞疾病造血干细胞移植与细胞治疗

老年多发性骨髓瘤患者移植资格:国际骨髓瘤工作组衰弱评分的前瞻性外部验证及与临床判断和其他合并症评分在65-75岁未选择患者中的比较

Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
PubMed 文献 · Am J Hematol · 2020-04-23

在131例65-75岁考虑自体干细胞移植的多发性骨髓瘤患者中,前瞻性外部验证IMWG衰弱评分并与临床判断、CCI和HCT-CI比较。85例被判断为适合移植,46例接受较低强度治疗,中位随访27个月。衰弱组无一例被认为适合移植,其PFS较fit和unfit患者更差;移植组PFS优于非移植组。

要点

  • 衰弱组患者无一例被判断为适合ASCT,其PFS较fit和unfit患者更差(中位PFS 7.9 vs 32.9和29.6个月,P<.001)。
  • ASCT组PFS优于非ASCT组(35.6 vs 19.9个月,P=.013)。
  • 在unfit且≥70岁患者中,ASCT组PFS与非ASCT组相当(18 vs 27个月,P=.33)。

核心结论

  • IMWG衰弱评分可能有助于识别70-75岁unfit患者,这些患者经临床判断选择ASCT后的结局并不优于较低强度治疗。

研究设计与样本

  • 前瞻性外部验证研究,纳入本中心131例65-75岁考虑ASCT的多发性骨髓瘤患者。
  • 诊断时获取CCI、HCT-CI和IMWG衰弱评分,治疗强度由医师选择。
  • 分析评分和年龄对结局的影响,中位随访27个月。

主要发现

  • 85例被判断为适合移植,46例接受较低强度治疗。
  • 衰弱组无一例被认为适合ASCT,其PFS较fit和unfit患者更差(中位PFS 7.9 vs 32.9和29.6个月,P<.001)。
  • ASCT组PFS优于非ASCT组(35.6 vs 19.9个月,P=.013)。
  • ASCT组中65-69岁患者PFS优于≥70岁患者(51.5 vs 27.7个月,P=.004)。
  • unfit且≥70岁患者中,ASCT组PFS与非ASCT组相当(18 vs 27个月,P=.33);unfit且65-69岁患者中,ASCT组PFS优于非ASCT组(43.3 vs 18.4个月,P=.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) is feasible and effective in selected older patients with Multiple Myeloma, but specific criteria for evaluating ASCT eligibility in elderly patients are lacking. We evaluated 131 patients aged 65-75 considered for ASCT at our center: The Charlson Comorbidity Index (CCI), Hematopoietic cell transplantation comorbidity index (HCT-CI) and IMWG frailty score were obtained at diagnosis, but the intensity of treatment was left to physician's choice. The scores and age's impact on outcome was analyzed: 85 patients were judged transplant eligible, whereas 46 patients received a less intensive treatment (median follow up 27 months). No patients classified as frail had been considered eligible to ASCT with a worse outcome compared to fit and unfit patients (median PFS (progression free survival): 7.9 vs 32.9 and 29.6 months; P < .001). PFS was superior in the ASCT group (35.6 vs 19.9 months, P .013). In the ASCT group, PFS was better in patients aged 65-69 years than in patients ≥70 (51.5 vs 27.7 months, P.004). Indeed, in unfit patients aged ≥70 the PFS of the ASCT group was comparable to NO ASCT group (18 vs 27 months, P = .33) whereas in unfit patients aged 65-69 PFS was superior in the ASCT group: 43.3 vs 18.4 months, P .01. ISS III and impaired functional status independently affected PFS in a multivariate analysis (P .011 and P .006). While CCI and HCT-CI did not predict different outcome in ASCT patients, the IMWG frailty score would be of help in identifying unfit patients aged 70-75, whose outcome with ASCT selected by clinical judgment was no better than with less intensive treatments.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Belotti A, Ribolla R, Cancelli V, et al. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. Am J Hematol. 2020. PMID: 32242970. doi:10.1002/ajh.25797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。